TD Cowen Maintains Outperform on Novo Nordisk, Raises Price Target to $115
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Michael Nedelcovych has maintained an Outperform rating on Novo Nordisk (NYSE:NVO) and increased the price target from $105 to $115.
December 04, 2023 | 5:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novo Nordisk's Outperform rating is maintained by TD Cowen, with a raised price target from $105 to $115, indicating a positive outlook on the stock.
The increase in price target by TD Cowen suggests a strong confidence in Novo Nordisk's future performance, which could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100